Gregory Mazo

Title: Gregory Mazo: Innovator in Cancer Immunotherapy

Introduction

Gregory Mazo is a prominent inventor based in New York, NY (US), known for his significant contributions to cancer immunotherapy. His innovative work focuses on the development of recombinant poxviruses aimed at treating and preventing cancer. Mazo's research is pivotal in advancing therapeutic strategies that harness the immune system to combat cancer.

Latest Patents

Mazo holds a patent for "Recombinant poxviruses for cancer immunotherapy." This patent discloses methods and compositions related to the treatment, prevention, and amelioration of cancer in subjects in need. The technology involves genetically engineered or recombinant poxviruses, including modified vaccinia Ankara (MVA) viruses with specific deletions and engineered to express OX40L and other ligands. These compositions serve as oncolytic and immunotherapeutic agents, showcasing Mazo's commitment to innovative cancer treatments.

Career Highlights

Gregory Mazo is affiliated with the Memorial Sloan Kettering Cancer Center, a leading institution in cancer research and treatment. His work at this prestigious center allows him to collaborate with top researchers and contribute to groundbreaking advancements in cancer therapy. Mazo's dedication to his field is evident through his innovative research and the impact it has on patient care.

Collaborations

Mazo has collaborated with notable colleagues, including Liang Deng and Jedd David Wolchok. These partnerships enhance the scope and effectiveness of his research, fostering an environment of innovation and discovery in cancer immunotherapy.

Conclusion

Gregory Mazo's contributions to cancer immunotherapy through his innovative patents and collaborations highlight his role as a leading inventor in the field. His work continues to inspire advancements in cancer treatment, ultimately benefiting patients in need.